Patents by Inventor Yanwen Fu

Yanwen Fu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same
    Patent number: 11607457
    Abstract: Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein (e.g., an Hdm2 targeting peptide) attached at its C-terminus to a phosphorothioate nucleic acid. Attachment of the phosphorothioate nucleic acid to the non-cell penetrating protein conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating peptide. The nucleic acid-peptide conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: March 21, 2023
    Assignees: CITY OF HOPE, SORRENTO THERAPEUTICS, INC.
    Inventors: Andreas Herrmann, Hua Yu, Yanwen Fu
  • Chemically-Locked Bispecific Antibodies
    Publication number: 20220144971
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • Chemically-locked bispecific antibodies
    Patent number: 11267905
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: March 8, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • ANTI-CANCER PHOSPHOROTHIOATE-COUPLED PEPTIDE CONJUGATES AND METHODS OF USING THE SAME
    Publication number: 20210154305
    Abstract: Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein (e.g., an Hdm2 targeting peptide) attached at its C-terminus to a phosphorothioate nucleic acid. Attachment of the phosphorothioate nucleic acid to the non-cell penetrating protein conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating peptide. The nucleic acid-peptide conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 27, 2021
    Inventors: Andreas HERRMANN, Hua YU, Yanwen FU
  • CELL INTERNALIZING COMPOUNDS
    Publication number: 20210138075
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 13, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
  • Disulfide Bridging Conjugates
    Publication number: 20210052738
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Application
    Filed: August 31, 2020
    Publication date: February 25, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • Cell internalizing compounds
    Patent number: 10925968
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: February 23, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
  • Disulfide bridging conjugates
    Patent number: 10799598
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 13, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • Cell penetrating peptide inhibitors of p53-MDM2 interaction
    Patent number: 10583193
    Abstract: Provided are compounds having the Formula I or II: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: March 10, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann
  • CELL INTERNALIZING COMPOUNDS
    Publication number: 20190358336
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Application
    Filed: June 27, 2019
    Publication date: November 28, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
  • Chemically-locked bispecific antibodies
    Patent number: 10435479
    Abstract: There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the IgG class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific IgG class antibody having a linkage region joined together with bio-orthogonal click chemistry.
    Type: Grant
    Filed: May 10, 2015
    Date of Patent: October 8, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Bryan Jones, Raheleh Toughiri
  • CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES
    Publication number: 20190248923
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 15, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • Intracellular delivery compounds
    Patent number: 10336829
    Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 2, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar Jörg Floris Kaufmann, Heehyoung Lee, Ingale Sampat Lalaso
  • Chemically-locked bispecific antibodies
    Patent number: 10301395
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 28, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • DISULFIDE BRIDGING CONJUGATES
    Publication number: 20190038764
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Application
    Filed: August 1, 2018
    Publication date: February 7, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • C-MET ANTIBODY DRUG CONJUGATE
    Publication number: 20180280531
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.
    Type: Application
    Filed: December 8, 2015
    Publication date: October 4, 2018
    Inventors: Tong Zhu, Gang Chen, Yanwen Fu, Edwige Gros
  • CELL PENETRATING PEPTIDE INHIBITORS OF p53-MDM2 INTERACTION
    Publication number: 20180207285
    Abstract: Provided are compounds having the Formula I or II: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.
    Type: Application
    Filed: January 25, 2018
    Publication date: July 26, 2018
    Inventors: Yanwen Fu, Gunnar F. Kaufmann
  • Linked Dual Antibodies Conjugated at a Hinge Region
    Publication number: 20180194859
    Abstract: There is disclosed methods for derivatizing and conjugating two hinge-containing antibody molecules. There is further disclosed derivatized and conjugated hinge-containing antibody molecules.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 12, 2018
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Gunnar F. Kaufmann, Yanwen Fu, James Patterson, Tong Zhu
  • c-Met Antibody Drug Conjugate
    Publication number: 20170281796
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.
    Type: Application
    Filed: December 8, 2015
    Publication date: October 5, 2017
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Gang Chen, Yanwen Fu, Edwige Gros
  • Toilet ladder
    Patent number: D978302
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: February 14, 2023
    Assignee: ZHEJIANG YIWU SHUMEIJIA TECHNOLOGY SHARE CO., LTD
    Inventors: Junrong Fu, Jiajian Fu, Yanwen Luo, Huan Sun